As expected, the soluble DLAT protein level decreased and the insoluble DLAT increased under elevated elesclomol-Cu incubation (Fig.S4B), and co-incubated sorafenib or erastin dramatically enhanced elesclomol-Cu augmented insoluble DLAT in liver cancer cells (Fig. 2B-C and Fig.S4C). This evidence concerns the gene DLAT and liver cancer.